Acute respiratory distress syndrome; A rare complication caused by usage of ruxolitinib.

Respir Med Case Rep 2017 18;22:243-245. Epub 2017 Sep 18.

Department of Pulmonary Diseases, Ataturk University School of Medicine, 25240, Erzurum, Turkey.

Ruxolitinib-associated acute respiratory distress has rarely been reported, mostly due to discontinuation of treatment. Herein we report a 58-year-old male patient with primary myelofibrosis who presented with malaise and dyspnea 15 days after initiation of the treatment. The patient was diagnosed as mild acute respiratory distress syndrome (ARDS). After excluding other potential causes such as infection and cardiac pathologies, it was considered secondary to ruxolitinib use. The medication was discontinued and 1 mg/kg methylprednisolone was given to prevent cytokine rebound syndrome and continuous positive airway pressure therapy was prescribed for ARDS. Symptomatic improvement and complete radiological resolution was observed. This case suggests that ARDS may develop secondary to ruxolitinib use and ARDS should be keep in mind in the cases with respiratory symptoms who were on treatment.

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.rmcr.2017.09.003DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5608559PMC
September 2017
Save 15% Survey

Similar Publications

Recessive VAMP1 mutations associated with severe congenital myasthenic syndromes - A recognizable clinical phenotype.

Eur J Paediatr Neurol 2021 Feb 16;31:54-60. Epub 2021 Feb 16.

Department of Neurology, National Institute of Mental Health and Neurosciences, Bengaluru, India. Electronic address:

Three unrelated girls, all born to consanguineous parents had respiratory distress, severe hypotonia at birth along with prominent fatigable muscle weakness and characteristic myopathic facies. In addition, patient 1 had fatigable ptosis, ophthalmoparesis and profound bulbar weakness and required nasogastric feeding from birth. A feeding gastrostomy was inserted at 9 months of age. Read More

View Article and Full-Text PDF
February 2021

Efficacy of Serum Angiotensin II Levels in Prognosis of Patients With Coronavirus Disease 2019.

Crit Care Med 2021 Feb 26. Epub 2021 Feb 26.

Cerrahpasa Faculty of Medicine, Department of Emergency Medicine, Istanbul University-Cerrahpasa, Istanbul, Turkey. Cerrahpasa Faculty of Medicine, Department of Medical Biochemistry, Istanbul University-Cerrahpasa, Istanbul, Turkey. Cerrahpasa Faculty of Medicine, Department of Infectious Diseases and Clinical Microbiology, Istanbul University-Cerrahpasa, Istanbul, Turkey. Cerrahpasa Faculty of Medicine, Department of Intensive Care, Istanbul University-Cerrahpasa, Istanbul, Turkey.

Objectives: We aimed to determine serum angiotensin II levels in patients with coronavirus disease 2019 infection and to investigate the effect of these levels on the prognosis of the disease.

Design: The study was planned prospectively and observationally.

Setting: The study was conducted in a tertiary university hospital. Read More

View Article and Full-Text PDF
February 2021

Early Improvement of Acute Respiratory Distress Syndrome in Patients with COVID-19: Insights from the Data of ICU Patients in Chongqing, China.

JMIR Public Health Surveill 2021 Feb 17. Epub 2021 Feb 17.

Department of Intensive Care Unit, Chongqing Sixth People's Hospital, Chongqing, CN.

Background: Since the start of the pandemic of coronavirus disease 2019 (COVID-19), over 2 million people has died globally. Acute respiratory distress syndrome (ARDS) may be the main cause of death.

Objective: This study aimed to describe the clinical features, outcomes, and acute respiratory distress syndrome (ARDS) characteristics of patients with COVID-19 admitted to the intensive care unit (ICU) in Chongqing, China. Read More

View Article and Full-Text PDF
February 2021

Time to Cannulation after ICU Admission Increases Mortality for Patients Requiring Veno-Venous ECMO for COVID-19 Associated Acute Respiratory Distress Syndrome.

Ann Surg 2020 Dec 22. Epub 2020 Dec 22.

*University of North Carolina at Chapel Hill, Division of Acute Care Surgery, Department of Surgery, Chapel Hill, NC †University of North Carolina at Chapel Hill School of Medicine ‡University of North Carolina at Chapel Hill, Division of Hospital Medicine, Department of Medicine, Chapel Hill, NC §University of North Carolina at Chapel Hill, Division of Acute Care Surgery, Department of General Surgery, Chapel Hill, NC.

Objective: COVID-19 can cause acute respiratory distress syndrome (ARDS) that is rapidly progressive, severe, and refractory to conventional therapies. Extracorporeal membrane oxygenation (ECMO) can be used as a supportive therapy to improve outcomes but evidence-based guidelines have not been defined.

Summary Background Data: Initial mortality rates associated with ECMO for ARDS in COVID-19 were high, leading some to believe that there was no role for ECMO in this viral illness. Read More

View Article and Full-Text PDF
December 2020

Diabetes in COVID-19 pandemic-prevalence, patient characteristics and adverse outcomes.

Int J Clin Pract 2021 Feb 25:e14112. Epub 2021 Feb 25.

Foundation for Diabetes Research in Older People, Diabetes Frail Ltd, Droitwich Spa, WR9 0QH, UK and Kings College, London, SE1 9NH, UK.

Background: Current literature on COVID-19 pandemic has identified diabetes as a common comorbidity in patients affected. However, the evidence that diabetes increases the risk of infection, effect of diabetes on outcomes and characteristics of patients at risk is not clear.

Objectives: To explore the prevalence of diabetes in COVID-19 pandemic, effect of diabetes on clinical outcomes and to characterise the patients with diabetes affected by COVID-19. Read More

View Article and Full-Text PDF
February 2021